{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0189","upperLimit":"0.0203","value":"0.0195"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"}],"units":"Participants"}],"description":"The PK systemic clearance parameter estimates from the current analysis are listed together with the population PK model estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"75 milligrams per meter squared (mg/m\\^2) doxorubicin administered intravenously (IV) on day 1 of each 21 day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21 day cycle until documented progressive disease (PD) or discontinuation for any other reason.","id":"OG000","title":"Doxorubicin + Olaratumab"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least one dose of study drug and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1- 9: Day 1 and 8, Predose, 5 minutes Post dose and then every other cycle and follow-up (30 Days)","title":"Pharmacokinetics (PK) Clearance of Olaratumab Mean Parameter Estimate","type":"SECONDARY","unitOfMeasure":"Liter/hour (L/h)"}